Injectable Contraceptives Market - By Type (Progesterone-only Injectables {Depot Medroxyprogesterone Acetate}), Age Group (15-24 Years, 25-34 Years), Duration of Action (Short-acting Injectable Contraceptives), End-user, Global Forecast, 2023-2032

Injectable Contraceptives Market Size

Injectable Contraceptives Market size was valued to be USD 339.5 million in 2022 and is predicted to experience a sustainable growth of CAGR 3.5% from 2023 to 2032. Some of the major factors contributing to the growth of global market are growing awareness about family planning that is leading to an increase in awareness about benefits of injectable. Furthermore, the efforts undertaken by government and other organisations to enhance the availability of injectable contraceptives are contributing to the market expansion.
 

Injectable contraceptives are a type of birth control method that involves the administration of hormones through an injection to prevent pregnancy. These hormones typically include progestin, a synthetic form of the hormone progesterone. Injectable contraceptives are mainly available in two forms, depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN).
 

COVID-19 Impact

The COVID-19 pandemic had a major impact on the injectable contraceptives market and resulted in a decline in the revenue of the market. The COVID-19 pandemic led to the decline in the number of family planning where injectable contraceptives are utilized. For instance, the United Nations Population Fund (UNFPA) and Avenir Health data, in 2020, reported that approximately 12 million women were unable to receive family planning services with around 1.4 million unplanned pregnancies. Additionally, the pandemic also disrupted the supply chains and manufacturing of injectable contraceptives, which affected the availability of the supplies and the resources for family planning. 
 

Injectable Contraceptives Market Driving Factors

The initiatives by government and other organizations to increase access to injectable contraceptives are the key factor driving the growth of market. For instance, according to a report published by The Bill & Melinda Gates Foundation, in August 2023, to help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries, the Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation (CIFF), Pfizer and Becton, Dickinson & Company (BD) have expanded their collaboration, that originally started in 2014. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana press (medroxyprogesterone acetate)1 administered by BD Uniject auto-disable prefillable injection system, through 2030. Such initiatives by organizations in the field of injectable contraceptives are helping the overall market to grow.
 

Injectable Contraceptives Market Restraining Factors

The aftereffects associated with the use of injectable contraceptives are expected to restrain the growth of the market. For instance, according to report by world health organisation (WHO), the side effects associated with the use injectable contraceptives are, irregular menstrual bleeding patterns and amenorrhea (the absence of menstrual bleeding). Additionally, other than menstrual disruption, some other side effects were also observed such as, weight gain, heavier menstrual bleeding, headaches, dizziness, breast tenderness, body aches, nervousness, fatigue, and acne. Such side effects are somehow making women less interested towards the use if injectable contraceptives, thereby hampering market progress.
 

Injectable Contraceptives Market Analysis

Based on type, the injectable contraceptives market is segmented into progesterone-only injectables and combined injectable contraceptives. The progesterone-only injectables segment is further bifurcated into depot medroxyprogesterone acetate and norethisterone enanthate. In 2022, the progesterone-only injectables segment accounted for the largest business share of 68.8% in the market and is expected to grow at a CAGR of 3.3% in the forecast period. This growth can be attributed to the advantages incorporated such as, high level of efficacy and reliability in preventing unintended pregnancies.
 

Additionally, the progesterone-only injectables are suitable for a broader range of individuals, including those who may have contraindications to estrogen-containing contraceptives due to medical conditions or lifestyle factors. Moreover, the convenience of fewer injections, typically administered every three months, is another advantage, appealing to people preferring less frequent interventions, that has led to the growth of this segment.
  

Based on group, the injectable contraceptives market is segmented into 15-24 years, 25-34 years, 35-44 years, and above 44 years. The 15-24 years segment accounted for the largest share in 2022 and is expected to showcase growth at a CAGR of 3.2% during the forecast period. This growth is attributed to factors such as, convenience of injections administered every few months resonates with young adults immersed in education, career pursuits, and social activities. Additionally, the high efficacy of injectable contraceptives provides reassurance against unintended pregnancies to women that are not yet prepared for the parenthood. Moreover, the injectable contraceptives offer privacy and discretion, allowing individuals in this age group to manage their reproductive health confidentially, that has led to the growth of this segment and the overall market.
 

Based on duration of action, the injectable contraceptives market is classified into short-acting injectable contraceptives and long-acting injectable contraceptives. In 2022, the short-acting injectable contraceptives segment accounted for the largest market revenue of USD 207.1 million and is expected to grow at a CAGR of 3.4% in the forecast period. This expansion can be attributed to factors such as convenient of administration, resonating with individuals seeking birth control that offers reliability without committing to a longer-term method.
 

Additionally, the short-acting injectables are well-suited for people who value minimal disruption to their routine or privacy, as they can receive injections discreetly. The manageable time frame between doses helps ensure consistent usage, making them an attractive option for those who might not want to commit to a daily routine, such factors have directly added to the growth of the segment.
 

Based on end-user, the injectable contraceptives market is classified into hospital, gynaecology clinics, and other end-users. In 2022, the hospital segment accounted for the largest market revenue of USD 159.7 million and is expected to grow at a CAGR of 3.1% in the forecast period. The growth of this segment can be attributed to factors such as reliability and controlled administration of injectable contraception. By getting it administered in the hospital, the involvement of medical personnel ensures accurate dosing, reducing the risk of user error and enhancing contraceptive effectiveness.
 

Additionally, the use of injectable contraceptives in hospitals allows for seamless integration with other reproductive health services, offering a comprehensive approach to patient care. That is directly enhancing more patients to opt for hospitals and leading to growth of this segment.
 

Based on the region, the injectable contraceptives market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2022, North America accounted for a revenue of USD 137.3 million, and it is expected to reach USD 186.9 million by 2032. This expansion can be attributed to factors such as, the region's well-established healthcare systems facilitate widespread access to a variety of contraceptive options, including injectables. Furthermore, the emphasis on reproductive health education and family planning initiatives contributes to a high level of awareness among individuals, enabling them to make informed contraceptive choices.
 

Also, the region's trained medical professionals ensure accurate administration and monitoring of injectable contraceptives, enhancing their reliability leading to growth of market in the North America.
 

Injectable Contraceptives Market Share

The prominent players in injectable contraceptives market are

• Pfizer Inc.
• Amphastar Pharmaeceutical Inc.
• Zhejiang xianju Pharmaceutical co., ltd.
• Eugia pharma
• Mylan labs ltd.
• Bayer Plc
• Teva Pharms USA
• PT Tunggal
• Incepta Pharmaceuticals
• Baxter International Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

Injectable Contraceptives Industry News:

• In August 2023, Pfizer and Becton, Dickinson & Company (BD) expanded their nearly decade-long collaboration with the bill and Melinda gates foundation, to help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate)1 administered by BD Uniject Auto-Disable Prefillable Injection System, through 2030 and is also expected to benefit the whole market.
   
• In October 2018, Mylan N.V. launched medroxyprogesterone acetate injectable suspension USP, 150mg/mL single dose vial, a generic version of the brand, Pfizer’s Depo- Provera in the U.S. Mylan is offering the injectable suspension to its institutional customers after an Abbreviated New Drug Duration of action (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA). That has led to an increase in revenue growth for both Mylan and the global market.
   

The injectable contraceptives market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type

• Progesterone-only injectables
  • Depot medroxyprogesterone acetate
  • Norethisterone enanthate
• Combined injectable contraceptives

By Age Group

• 15–24 years
• 25–34 years
• 35–44 years
• Above 44 years

By Duration of Action

• Short-acting injectable contraceptives
• Long-acting injectable contraceptives

By End-User

• Hospital
• Gynecology clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa